Survival In Post-Endoscopy Esophageal Cancer: A Nordic Population-Based Cohort Study
Endoscopy · 01.06.2026 · 58 (06) · 588-594
DOI: 10.1055/a-2807-8630 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von Dag Holmberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Karolinska Institutet, Department of Molecular Medicine and Surgery, Sweden, Stockholm. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophagoscopy, Adenocarcinoma. Gefördert von: Swedish Society of Medicine, Swedish Cancer Society.
Abstract (Originalsprache)
Background and Study Aims: Post-endoscopy esophageal cancer (PEEC), i.e., esophageal cancer diagnosed shortly after an endoscopy in which no cancer was found, constitutes about 5-10% of all esophageal cancers. The long-term survival in PEEC has previously not been reported. Patients and Methods: This population-based cohort study included all patients with a newly diagnosed esophageal cancer in Denmark, Finland, or Sweden between 2004-2022. Patients with PEEC, i.e., a history of upper endoscopy between 6-36 months before esophageal cancer diagnosis, were compared with all other esophageal cancer, i.e., those without upper endoscopy 6-36 months before diagnosis. The outcomes were 5-year disease-specific mortality and 5-year all-cause mortality. Multivariable Cox regression was used to calculate hazard ratios (HR) with 95% confidence intervals (95% CI), adjusted for country, age, sex, calendar year, comorbidity and tumor histology.
Results
Among all 27,309 study patients with esophageal cancer, 1588 (5.8%) were classified as PEEC. The cumulative 5-year mortality among patients with PEEC was 74.6% (n=1185), and 79.6% of the deaths (n=943) were disease-specific. PEEC was associated with decreased risks of both 5-year disease-specific mortality (HR 0.72, 95% CI 0.68-0.77) and 5-year all-cause mortality (HR 0.74, 95% CI 0.71-0.80). Stratified analysis found that the decreased 5-year disease-specific mortality in PEEC was limited to patients with adenocarcinoma (HR 0.57, 95% CI 0.52-0.62), whereas no such decrease was found among patients with squamous cell carcinoma (HR 1.04, 95% CI 0.95-1.15).
Conclusions
The 5-year survival in patients with PEEC seems to be better than in those with other esophageal cancer, but the survival is still poor. Keywords: PEUGIC; PEEC; missed lesions; esophageal neoplasm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Karolinska Institutet, Department of Molecular Medicine and Surgery, Sweden, Stockholm.
- University of Colorado Anschutz Medical Campus, Division of Gastroenterology and Hepatology, United States, Aurora, Colorado.
- Norwegian University of Science and Technology, Department of Public Health and Nursing, Norway, Trondheim.
- Levanger Hospital, Nord-Trøndelag Hospital Trust, Medical Department, Norway, Levanger.
- University of Copenhagen, Department of Public Health, Denmark, Copenhagen.
- Oulu University Hospital and University of Oulu, Department of Surgery, Finland, Oulu.
ORCID-Profile: Dag Holmberg
Förderung
- Swedish Society of Medicine
- Swedish Cancer Society
Zitieren
APA
Holmberg, D., Liljequist Aspelund, A., Wani, S., Ness-Jensen, E., Von Euler-Chelpin, M., Kauppila, J. H., Santoni, G., & Lagergren, J. (2026). Survival In Post-Endoscopy Esophageal Cancer: A Nordic Population-Based Cohort Study. Endoscopy, 58(06), 588-594. https://doi.org/10.1055/a-2807-8630
Vancouver
Holmberg D, Liljequist Aspelund A, Wani S, Ness-Jensen E, Von Euler-Chelpin M, Kauppila JH, et al. Survival In Post-Endoscopy Esophageal Cancer: A Nordic Population-Based Cohort Study. Endoscopy. 2026;58(06):588-594. doi:10.1055/a-2807-8630
BibTeX
@article{Holmberg2026,
author = {Holmberg, Dag and Liljequist Aspelund, Amalia and Wani, Sachin and Ness-Jensen, Eivind and Von Euler-Chelpin, My and Kauppila, Joonas H and Santoni, Giola and Lagergren, Jesper},
title = {Survival In Post-Endoscopy Esophageal Cancer: A Nordic Population-Based Cohort Study},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {06},
pages = {588--594},
doi = {10.1055/a-2807-8630}
}
EUVIMED